Since LSD1 levels and activity were associated with angiogenesis, tumor growth [35], as well as the metabolic shift toward glycolysis [39], LSD1 inhibitors are promising candidates for suppressing cancer progression in relation to the hypoxic response. This evidence concerns the gene KDM1A and neoplasm.